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the original work isIntroduction: Fourth-generation HIV-1 rapid diagnostic tests (RDTs) detect HIV-1 p24
antigen to screen for acute HIV-1. However, diagnostic accuracy during clinical use
may be suboptimal.
Methods: Clinical sensitivity and specificity of fourth-generation RDTs for acute HIV-1
were collated from field evaluation studies in adults identified by a systematic literature
search.
Results: Four studies with 17381 participants from Australia, Swaziland, the United
Kingdom and Malawi were identified. All reported 0% sensitivity of the HIV-1 p24
component for acute HIV-1 diagnosis; 26 acute infections were missed. Specificity
ranged from 98.3 to 99.9%.
Conclusion: Fourth-generation RDTs are currently unsuitable for the detection of acute
HIV-1. Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2015, 29:2465–2471Keywords: acute infection, diagnostic accuracy, HIV, point-of-care testing,
rapid diagnostic tests, systematic reviewIntroduction
An estimated 5–20% of HIV infections are due to
transmission from recently infected individuals [1],
although this depends on epidemic characteristics [2,3].
Diagnosing HIV in the weeks after an individual has
acquired infection is likely to be critical to epidemic
control as prompt diagnosis allows early entry into care
and treatment, reducing the risk of onward transmission.
Laboratory diagnosis relies on the appearance of HIV
antigen (e.g. HIV-1 p24 antigen) or nucleic acid in the
bloodstream prior to detectable antibodies to HIV-1/2,
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properly cited.and accurate in-vitro diagnostics for detection of acute
HIV infection that can be used at point of care are
required to realize the potential public health benefits of
early diagnosis, especially in resource-limited settings
wherein the large majority of HIV transmissions occur.
New fourth-generation point-of-care rapid diagnostic
tests (RDTs) for HIV-1 detect HIV-1 p24 antigenaemia
as well as antibodies to HIV-1/2. They have the potential
to meet these requirements, and have been approved for
their sale in many settings. However, the sensitivity of the
p24 antigen component has been variable (2–92%) in
laboratory evaluations on banked panels of specimenses, Liverpool School of Tropical Medicine, cDepartment of
arasitology, Liverpool School of Tropical Medicine, Liverpool,
d Health Sciences, StellenboschUniversity, Cape Town, South
cts, World Health Organization, Geneva, Switzerland.
tre, Liverpool School of Tropical Medicine, Pembroke Place,
ugust 2015.
ts reserved. This is an open access article distributed under the
se, distribution, and reproduction in any medium, provided
2465
2466 AIDS 2015, Vol 29 No 18[4–9] leading to concerns that this may translate into
poor diagnostic accuracy in the field for the diagnosis of
acute HIV-1 [10]. We therefore performed a systematic
review to assess the field accuracy of fourth-generation
RDTs for the diagnosis of acute HIV-1 in clinical
practice.MEDLINE
1586 Abstracts
identified 
ISI Web of Science
929 Abstracts
identified 
2056 Abstracts
reviewed 
459 Duplicates excluded
34 Full text
reviewed 
2022 Excluded
1768 Not relevant
9 Children only
15 Ineligible study design
4 Qualitative data only
72 Review, commentary,
editorial, economic or
mathematical modelling
140 Fourth-generation RDT not
assessed 
14 Other reasons
4 Included in
qualitative
synthesis  
4 Included in
quantitative
synthesis  
30 Excluded
9 Not relevant
12 Ineligible study design
8 Fourth-generation RDT not
assessed 
1 Other reasons
Fig. 1. Flowchart of included and excluded studies.Methods
In accordance with our published protocol [11], we
systematically searched Medline (using PubMed) and ISI
Web of Science for studies published between 1 January
2005 and 22 April 2015 that evaluated the diagnostic
accuracy of fourth-generation RDTs for acute HIV-1
(Supplementary Table 1: Search Strategy, http://
links.lww.com/QAD/A767). Studies were eligible if
they evaluated the field performance of at least one
fourth-generation RDT for acute HIV-1 in adults (aged
>15 years). We defined field performance as the RDT
being used on an unselected population, at the point of
care (defined as being conducted in the presence of the
patient [12]), in the setting of intended use and carried
out by the intended user. Cross-sectional studies, cohort
studies and randomized control trials were included.
Studies that evaluated fourth-generation RDTs within
laboratories or retrospectively against specimen panels
were excluded. We placed no restrictions on assay
manufacturer, language or country.
Two reviewers (P.M., E.A.) independently reviewed the
titles and abstracts of all studies against inclusion and
exclusion criteria, with discrepancies resolved by group
decision with a third reviewer (M.T.). Two reviewers
(J.L., P.M.) independently reviewed the full text of all
selected studies using a piloted data extraction form to
determine final selection status. Discrepancies between
reviewers were resolved by group decision with a third
reviewer (M.T.). Participants receiving the index test
were defined as true positive, false positive, false negative
and true negative for the presence of a positive HIV-1 p24
antigen reaction on the fourth-generation HIV RDT
compared with the study-defined reference standard for
acute HIV-1 infection. We recognized that there is no
current consensus reference standard for the diagnosis of
acute HIV infection and specified that an acceptable
reference standard for the diagnosis of acute HIV-1
infection would include at least one nonreactive antibody
test result using a third-generation HIV immunoassay, and
at least one reactive antigen test result on a fourth-
generation HIV immunoassay, and/or at least one reactive
result using an HIV-1 p24 antigen immunoassay.
However, where this was not used, we used study-
reported reference standards. Details of studies excluded
after full-text review are shown in the supplementary
appendix (Supplementary Table 2, http://links.lww.
com/QAD/A767) [5–9,13–37].Risk of bias in the included studies was independently
assessed by two reviewers (J.L. and P.M.) using the
Quality Assessment of Diagnostic Accuracy Studies 2
(QUADAS 2) tool [38] with signalling questions used
across four domains (selection, index test conduct,
reference standard conduct and participant flow and
timing) to assess overall risk of bias.
Study flow and results are reported in accordance with the
Standards for Reporting of Diagnostic Accuracy
(STARD) checklist [39]. Given the high degree of
heterogeneity in study populations and conduct, we did
not perform meta-analysis, but would have done so if
results had indicated this to be appropriate.Results
Of 2056 unique studies identified, four met inclusion
criteria and contributed data relating to 17 381 participants
to this analysis (Fig. 1). Studies came from Swaziland [40],
Malawi [41], Australia [42] and the United Kingdom [43]
(Table 1). Three studies included community members
[41], MSM [42] or IDUs [43] attending specialist sexually
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Field accuracy of fourth-generation rapid diagnostic tests for acute HIV-1 Lewis et al. 2469transmitted diseases or HIV testing clinics, whereas in the
fourth, participants were recruited from a national HIV
incidence survey [40]. All had a cross-sectional study
design.
All four studies evaluated the diagnostic accuracy of Alere
Determine HIV-1/2 Ag/Ab Combo (Alere Medical Co.
Ltd., Chiba, Japan), hereafter described as the index test.
This is a fourth-generation RDT that can detect antibody
to HIV-1/2 and HIV-1 p24 antigen. Only two studies
used reference standards as defined in our study protocol
[42,43], with the other two studies variously using
laboratory-performed testing algorithms for characteriz-
ation of acute HIV comprising of a third-generation
RDT, a fourth-generation RDT and HIV quantitative
nucleic acid testing (NAT) technology (HIV viral load)
for participants with a reactive HIV-1 p24 antigen index
test result [40], and a third-generation RDT (all
participants) and HIV viral load quantification (partici-
pants with nonreactive or discrepant antibody index test
results) [41].
In all four studies, sensitivity of the HIV-1 p24 antigen
component of the index test for reference standard-
classified acute HIV infection was 0%, with a total of
26 acute HIV infections missed (Table 1). Specificity of
HIV-1 p24 antigen component of the index test for acute
HIV infection was similar across all studies (98.3–99.9%);
a total of 35 false-positive results were observed. It was
possible to extract data on the accuracy of the antibody
component of the index test from two of the four studies;
in the first, the antibody component detected zero of
three (0%) acute HIV infections [42]; in the second, two
of eight (25%) [41].
The risk of bias in these studies as assessed across the four
assessed domains was largely low or unclear. Only in one
domain of one study was there a high risk of bias: in
patient selection; in this study, a nonconsecutive,
nonrandom cohort of patients were enrolled – only
patients who were assessed as high risk for acute HIV
infection [41]. The full assessment of risk of bias is shown
in the supplementary appendix (Supplementary Table 3,
http://links.lww.com/QAD/A767).Discussion
This systematic review reveals unacceptably low-field
sensitivity in the diagnosis of acute HIV-1 of the p24
antigen component of Determine HIV 1/2 Ag/Ab
Combo (Alere Medical Co. Ltd, Chiba, Japan) – the
only product evaluated in the included studies – with not
a single true positive for acute infection detected in over
17 000 individuals from at-risk groups in sub-Saharan
Africa, Australia and the United Kingdom. Across these
studies, 26 reference-standard-defined acute HIVinfections were missed, and 35 false positives were
observed. On the basis of these findings, we recommend
that Determine HIV 1/2 Ag/Ab Combo (Alere Medical
Co. Ltd) is not currently used for screening for acute
HIV-1 infection at the point of care.
There are a number of likely reasons for the poor test
performance. The assay detects free HIV-1 p24 antigen;
this has a short window of detection, before developing
antibodies from immune complexes with antigen in the
bloodstream and preclude binding of antigen to the test
strip. This technical difficulty can be overcome with an
antigen dissociation step [44], but this may be hard to
implement at the point of care. Differential affinity of
binding to different HIV subtypes could also contribute
to poor detection of HIV-1 p24 antigen.
We excluded a number of studies as they did not meet our
inclusion criteria. The majority were not field evaluations
but rather evaluations in reference laboratory settings on
specimen panels. Of those studies that did perform a field
evaluation, but were excluded from this review, the
reference and/or index test(s) were often inconsistently
applied across all patients making evaluation of true
sensitivity and specificity impossible. This likely
represents the inherent difficulty in designing a study
to assess an in-vitro diagnostic for acute HIV infection,
which is rare even in areas of high HIV prevalence and has
a short timeframe for detection.
The lack of a consistent application of a clinical definition
of acute HIV-1 infection makes it challenging to compare
results across studies and compare diagnostic accuracy.
The included studies defined acute HIV-1 infection using
a variety of biomarkers and clinical parameters. In
laboratory terms, acute HIV-1 infection has been clearly
defined in terms of the Fiebig stages of acute HIV-1
infection, characterized by sequential appearance of
HIV-1 nucleic acid, HIV-1 p24 antigen followed by
immunoglobulin M and then immunoglobulin G
antibodies to HIV-1 [45]. These stages were originally
defined using second and third-generation immunoassays
and attempts have been made to redefine these stages in
terms of more modern third and fourth-generation assays
[46]. Regardless of the existence of these clear laboratory
definitions, we found that clinical definitions of acute
HIV-1 are inconsistently applied across studies. Inter-
nationally agreed and applied consensus definitions of
acute HIV infection for use in clinical studies would go
some considerable way to clarifying a confusing field.
Despite a comprehensive literature search and rigorous
analysis, there are some limitations to our study: data may
be reported as supplementary material, and have been
missed by our search; only adults were included. Owing
to the small number of studies identified, and high degree
of heterogeneity in study settings and populations, it was
inappropriate to undertake meta-analysis, meaning that
2470 AIDS 2015, Vol 29 No 18overall summary estimates for diagnostic accuracy cannot
be made. All studies assessed the accuracy of only one
fourth-generation RDT; others are available [e.g. SD
Bioline HIV Ag/Ab (Standard Diagnostics, Inc.,
Giheung-gu, Republic of Korea) and ImmunoComb
II HIV 1&2 TriSpot Ag-Ab (Orgenics Ltd, Yavne,
Israel)]. The generalizability of our results are unclear but
it seems likely that the same technical difficulties will
affect other fourth-generation RDTs [47], and clinicians
should interpret the results of HIV-1 RDTantigen testing
with caution.
In conclusion, the fourth-generation RDT for HIV that
was the subject of this systematic review has low
sensitivity for detection of acute HIV-1, and is unsuitable
for this purpose. Point-of-care options for diagnosis of
acute HIV-1 are therefore currently limited to third-
generation RDTs alongside careful assessment of timing
of exposure and serial testing, with a continuing need for
laboratory support for antigen testing or NAT wherein
the suspicion of acute HIV infection is high. New
approaches to diagnosis of acute HIV such as point-of-
care testing with third-generation RDT exhibiting best
possible seroconversion sensitivity, or NAT – including
the prospect of expansion of qualitative NAT platforms
for use at point of care that have been developed for early
infant diagnosis – need evaluating in the field against
agreed definitions of acute HIV in order to realize the
public health benefits of making this important diagnosis.Acknowledgements
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